Parkinson’s disease (PD) remains an incurable neurological disorder that disproportionately affects the aging population, profoundly impacting patients and their families. In pursuit of better management strategies, extensive research and clinical trials are underway. Many of these efforts have yielded promising breakthroughs that offer hope for improving quality of life, despite the limited understanding of PD’s underlying aetiology. This article highlights recent advances in PD management, including novel therapeutic approaches such as α-synuclein–targeted treatments, induced pluripotent stem cell replacement therapy, drug repurposing, deep brain stimulation, and non-pharmacological interventions. While much of this research is still in progress, these developments provide an encouraging outlook for the future of PD treatment and underscore the need for sustained, large-scale, and rigorous investigation to move beyond the current status quo.

For decades, pancreatic cancer has been one of the most feared diagnoses in medicine. Often called a “silent killer,” the disease typically develops with few symptoms and is frequently discovered only after it has reached an advanced stage. As a result, survival rates have historically lagged behind those of most other major cancers. However, a wave of scientific breakthroughs is beginning to change this narrative. Advances in imaging, biomarker discovery, genetic profiling, surgical techniques, immunotherapy, and precision medicine are creating new opportunities for earlier detection and more effective treatment. Most notably, the emergence of targeted therapies aimed at KRAS-driven tumours—long considered impossible to treat—has generated unprecedented optimism. Among these innovations, daraxonrasib has attracted worldwide attention after a major clinical trial demonstrated a near doubling of median overall survival in patients with previously treated metastatic pancreatic cancer. These developments suggest that pancreatic cancer may be entering a new era in which outcomes are steadily improving and personalised treatment becomes the standard of care. This article explores the scientific advances transforming pancreatic cancer care and examines what they could mean for patients in the years ahead.

Glaucoma is a progressive optic neuropathy characterised by visual field loss and structural damage to the optic nerve. The disease is a leading cause of irreversible blindness worldwide, affecting about 3.5% of individuals aged between 40 and 80 years1. While glaucoma-associated visual field loss may be asymptomatic until the late stages, the disease is commonly known as a silent thief of sight. Although early diagnosis of glaucoma remains a clinical challenge, recent advancements in therapeutics have significantly improved patient outcomes. In particular, laser treatment has been advocated to be safe and effective in managing glaucoma. In a recent sharing, Dr. Lai Sum Wai Isabel highlighted the pathophysiology of glaucoma and shared her insights into managing the disease.